Drugs / CU06-1004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04795037 | Jul 2021 → Mar 2022 | diabetic macular edema | Curacle Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07459829 | Dec 2026 → Jan 2028 expected | diabetic macular edema | Curacle Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05573100 | Dec 2022 → May 2023 | diabetic macular edema | Curacle Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CU06-1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07459829 ↗ |
| Route | Oral | “oral capsule” NCT04795037 ↗ |